Autophagy targets pathogens, damaged organelles and protein aggregates for lysosomal degradation. These ubiquitylated cargoes are recognized by specific autophagy receptors, which recruit LC3-positive membranes to form autophagosomes. Subsequently, autophagosomes fuse with endosomes and lysosomes, thus facilitating degradation of their content; however, the machinery that targets and mediates fusion of these organelles with autophagosomes remains to be established. Here we demonstrate that myosin VI, in concert with its adaptor proteins NDP52, optineurin, T6BP and Tom1, plays a crucial role in autophagy. We identify Tom1 as a myosin VI binding partner on endosomes, and demonstrate that loss of myosin VI and Tom1 reduces autophagosomal delivery of endocytic cargo and causes a block in autophagosome-lysosome fusion. We propose that myosin VI delivers endosomal membranes containing Tom1 to autophagosomes by docking to NDP52, T6BP and optineurin, thereby promoting autophagosome maturation and thus driving fusion with lysosomes.
Here, we identify the mammalian homologue of Tom1/Tom1L2, a constituent of an alternative ESCRT-0 complex 15 , as a myosin VI cargo adaptor and demonstrate a crucial role for myosin VI and Tom1 in autophagosome maturation and fusion with the lysosome. Tom1 mediates endosomal localization of myosin VI by interaction with the cargo-binding WWY motif and loss of myosin VI function leads to a decrease in endocytic cargo delivery to autophagosomes. Recruitment of myosin VI to autophagosomes is dependent on its RRL motif known to interact with NDP52, optineurin and T6BP. Therefore, myosin VI delivers Tom1-positive endosomal membranes to autophagosomes by docking to optineurin, NDP52 or T6BP, thus facilitating autophagosome maturation.
RESULTS

Loss of myosin VI function leads to an accumulation of autophagosomes
To understand the role of myosin VI and its binding partners in autophagy, we first assessed whether the loss of myosin VI, in the myosin-VI-knockout mouse or by short interfering RNA (siRNA)-mediated knockdown, affects cellular autophagy levels by measuring the abundance of the lipidated autophagosome-associated LC3 (LC3-II; ref. 16 ). In HeLa cells, myosin VI expression was suppressed with siRNA and conversion of LC3-I to LC3-II was quantified in the presence or absence of the vacuolar-type H+-ATPase inhibitor bafilomycin A1, which blocks the fusion of autophagosomes with lysosomes. There is a significant increase in the amount of LC3-II in myosin-VI-knockdown cells under steady-state conditions as well as in response to autophagy induction following treatment with the proteasome inhibitor MG132 (Fig. 1a,b and Supplementary Fig. S1a ). Elevated levels of LC3-II indicate an accumulation of autophagosomes, which was not due to an increase in autophagosome biogenesis, because there was no increase in LC3-II in the presence of bafilomycin A1 ( Fig. 1a,b ). We also observed by immunofluorescence microscopy an accumulation of LC3-positive autophagosomes and the autophagy cargo receptor p62 under basal conditions in myosin-VI-knockdown cells (Fig. 1c,d and Supplementary Fig. S1b ). These results were verified using single siRNA oligonucleotides targeting myosin VI ( Supplementary Fig. S1c ) and by rescue experiments using a HeLa cell line stably expressing GFP-myosin VI containing silent mutations in the target region of a single siRNA oligonucleotide (Fig. 1e ). The loss of myosin VI expression in parental cells leads to an accumulation of LC3-II ( Fig. 1a ,e), whereas in rescue cells expressing siRNA-resistant myosin VI, loss of endogenous myosin VI has no effect on LC3-II levels ( Fig. 1e ). Interestingly, the loss of myosin VI expression also leads to enlarged, swollen GFP-LC3-positive autophagosomes (Supplementary Figs S1d and S2a), which increased from an average area of 1.39 ± 0.049 (s.d.) µm 2 in mock-treated cells to 1.57 ± 0.055 (s.d.) µm 2 in myosin-VI-depleted cells ( Supplementary Fig. S1e ). We confirmed the myosin VI loss-of-function autophagy phenotype using mouse embryonic fibroblasts (MEFs) and primary cortical neurons collected from the Snell's waltzer (SV) myosin-VI-knockout mouse 17 . In SV fibroblasts, treatment with the MG132 inhibitor leads to a greater accumulation of LC3-II when compared with wild-type control MEFs ( Fig. 1f,g) , while exhibiting no significant difference in autophagosome biogenesis ( Fig. 1h ), thus suggesting a block in autophagy flux. Interestingly, in primary SV neurons, the steady-state levels of LC3-II are significantly higher when compared with wild-type neurons, thus confirming the phenotype observed in myosin-VI-siRNA-knockdown cells ( Fig. 1i-k) . These results indicate that myosin VI is not required for autophagosome formation, but possibly has a role during autophagosome-lysosome fusion.
Myosin VI facilitates autophagosome maturation and fusion with the lysosome
To monitor autophagosome-lysosome fusion in myosin-VIknockdown cells, we used HeLa cells that stably expressed a pH-sensitive RFP-GFP-LC3 reporter construct 18 and were treated with MG132 to induce autophagy. The loss of myosin VI expression leads to an accumulation of LC3-positive, yellow autophagosomes ( Fig. 1l ), and quantitative analysis of these confocal images indicates an abundant correlation between the GFP and RFP signals when compared with mock controls, indicating a defect in their maturation to an autolysosome, which owing to the drop in pH should only appear red ( Fig. 1m ). These yellow enlarged autophagosomes do not co-localize with lysosomal marker proteins, such as the protease cathepsin D or Lamp1, thus supporting a defect in autophagosome-lysosome fusion in myosin-VI-depleted cells ( Fig. 1n and Supplementary Fig.  S2a ). The lack of LC3 degradation in myosin-VI-depleted cells was not caused by a lysosomal defect, because we did not observe a delay or reduction in the degradation of the epidermal growth factor receptor (EGFR; Supplementary Fig. S2b ). These results strongly support a role for myosin VI in autophagosome maturation and fusion with the lysosome.
Myosin VI is required for autophagosomal degradation of p62-positive protein aggregates
Next, we investigated whether myosin VI dysfunction has an impact on autophagy-dependent clearance of ubiquitylated cargo. RPE cells were treated with MG132 for 16 h to allow for bulk accumulation of endogenous ubiquitylated protein aggregates 19 and 8 h after washing out this inhibitor, the remaining protein aggregates were visualized with antibodies against p62 ( Fig. 2a ) and quantified by automated microscopy (Fig. 2b) . The loss of myosin VI using either a pool of four different siRNAs or a single siRNA causes a significant increase in the number of p62-positive aggregates similar to that observed with the knockdown of Atg5, one of the essential autophagy regulators (Fig. 2b ). This defect in aggregate clearance was rescued by the expression of a siRNA-resistant myosin VI construct ( Fig. 2c ).
We investigated whether the loss of myosin VI expression has an effect on the clearance of the huntingtin protein containing a pathological polyQ expansion, which renders this protein prone to misfolding and aggregation 20 . In HeLa cells, we expressed a GFP-tagged huntingtin protein with a 72-amino-acid polyglutamine repeat (HttQ72-GFP), which is mostly cytosolic, characterized by <10% of cells containing multiple huntingtin aggregates (>15 per cell). However, after myosin VI knockdown there is a marked increase in the number of cells (from 10% to 70%) with multiple p62-and LC3-positive HttQ72-GFP aggregates (Fig. 2d ,e and Supplementary Fig. S3 ). Interestingly, myosin VI siRNA knockdown leads not only to an increase in the number of HttQ72-GFP punctae, but also to an accumulation of p62-positive punctae (Figs 1d, 2d and Supplementary Fig. S1b ). Collectively, these results support a role for myosin VI in the clearance of ubiquitylated p62-positive protein aggregates by autophagy.
Myosin VI localizes to LC3-positive autophagosomes
To further characterize the precise role of this motor protein in the autophagocytic pathway, we next analysed myosin VI targeting and localization to autophagosomes. In human RPE cells, GFP-myosin VI is recruited to cherry-LC3-positive autophagosomes ( Fig. 3a ) and endogenous myosin VI co-localizes with endogenous LC3 (Fig. 3b ) under conditions that induce non-selective autophagy such as treatment with Torin1, a selective mTOR kinase inhibitor, or following amino-acid withdrawal ( Supplementary Fig. S4a ). Furthermore, myosin VI co-localizes with LC3-positive autophagosomes containing the aggregate prone protein Ataxin3 with an 84-amino-acid polyglutamine repeat, Ataxin3Q84 ( Supplementary Fig. S4b ), highlighting a role for myosin VI in non-selective as well as in selective autophagy. A high proportion of LC3-positive autophagosomes co-localize with myosin VI (LC3/MVI), but only a distinct subpopulation of myosin VI is present on LC3-positive vesicles (MVI/LC3), reflecting the association of this multifunctional motor not only with autophagosomes but also with endocytic and secretory membrane trafficking compartments ( Supplementary Fig. S4c ). Often, the localization of myosin VI does not completely overlap with that of LC3 on autophagosomes, but is present in distinct areas or subdomains of the autophagosomal membrane ( Fig. 3a,b ), reminiscent of a small membrane vesicle docking at a larger autophagocytic vacuole.
Using live-cell video microscopy of RPE cells expressing GFP-myosin VI and cherry-LC3 we monitored their localization over a period of 10 min. Selected still images of these movies illustrate Supplementary Table S1 for details of the SMARTpool (SP) and single (07) oligonucleotides. (c) Parental HeLa cells or HeLa cells stable expressing siRNA-resistant GFP-myosin VI were transiently transfected with a single siRNA oligonucleotide targeting myosin VI and were subsequently treated with 1 µM MG132 for 16 h. Cells were processed for immunofluorescence microscopy at 16 h post-MG132 treatment (t = 0) or allowed to recover following washout of MG132 for 8 h (t = 8). Cells were processed for quantification with the automated Cellomics VTi microscope to evaluate the p62 fluorescence intensity. The results represent the fold increase in p62 fluorescence intensity of myosin VI siRNA compared with mock control cells following recovery from MG132 washout (t = 8; ±s.d.; n = 3). (d) HeLa cells with stable expression of HttQ72-GFP were transiently transfected with siRNA against myosin VI followed by saponin extraction and processing for immunofluorescence microscopy. Immunolabelling was performed for GFP (green) and p62 (red). Nuclei are labelled with Hoechst (blue). (e) Quantification of HttQ72-GFP aggregates was performed on myosin-VI-siRNA-transfected HeLa cells. The results were calculated as the percentage of GFP-expressing cells with greater than 15 GFP-positive spots per cell. The results represent the mean (±s.d.) from n = 3 independent experiments, * * * P < 0.001. The insets show higher magnifications of the areas outlined in the main images. Scale bars, 20 µm. Uncropped images of blots are shown in Supplementary Fig. S9 .
that several myosin-VI-associated vesicles (arrowheads) approach and contact LC3-positive autophagosomes ( Fig. 3c and Supplementary  Fig. S4d and Movies S1-S6), confirming a dynamic association of myosin VI with autophagosomes. As myosin VI is an actin-dependent motor, we probed for the presence of the actin cytoskeleton in the vicinity of autophagocytic organelles. We observed that myosin VI and actin, the motor and the track, are associated with LC3-positive autophagosomes (Fig. 3d , arrowheads).
Myosin VI targets to autophagosomes through the RRL motif in the cargo-binding tail domain
Two primary protein-protein interaction regions with either a WWY or RRL motif are present in the carboxy-terminal cargo-binding tail region of myosin VI, which also contains a ubiquitin-binding domain 21 (UBD; Fig. 4a ). To identify how myosin VI is recruited to autophagosomes, GFP-myosin VI tail constructs, containing either a WWY to WLY substitution ( WWY), a RRL to AAA substitution ( RRL) or an A1013G point mutation in the UBD, were transiently expressed in RPE cells stably expressing cherry-LC3. To visualize the precise intracellular localization of the GFP-myosin VI tails, the cells were briefly extracted with saponin to remove the cytosolic pool of the GFP-myosin VI tail before fixation. The wild-type myosin VI tail and the tail mutants with the WWY and A1013G mutations show prominent co-localization with LC3-positive autophagosomes (Fig. 4b,c ), which is significantly decreased without the RRL motif that mediates interactions with T6BP, NDP52 and optineurin ( Fig. 4a-c) . 
Binding partners co-localize with myosin VI on autophagosomes
The myosin VI binding partners optineurin, NDP52 and T6BP all contain a UBD and an LC3-interaction region (LIR), which are typically found in autophagy receptors such as p62 and NBR1 (ref. 22 ). As previous reports demonstrated a role for NDP52 and optineurin in the autophagy-dependent clearance of Salmonella from mammalian cells 7,8 , we investigated whether the function of these autophagy receptors is restricted to pathogen clearance or whether they have a general role in autophagy. Endogenous T6BP, NDP52 and optineurin are present on LC3-positive autophagosomes under basal autophagy conditions in the presence of bafilomycin A1 (Fig. 5a ). Interestingly, whereas localization of NDP52 and T6BP to autophagosomes does not require their C-terminal zinc-finger motifs that mediate ubiquitin binding, the ubiquitin-binding motif of optineurin, within the myosin VI interaction domain, disrupts its localization to autophagosomes ( Supplementary Fig. S5a ).
To determine whether these binding partners/autophagy receptors recruit myosin VI to autophagosomes, RPE cells stably expressing cherry-LC3 were transiently transfected with GFP-myosin VI and subsequently treated with Torin1 before processing for immunocytochemistry with antibodies to endogenous optineurin or T6BP (Fig. 5b) . The triple labelling clearly shows that myosin VI and its binding partners T6BP and optineurin are present on the same LC3-positive autophagosomes after treatment with Torin1 ( Fig. 5b) .
Optineurin, NDP52 and T6BP are required for autophagosome biogenesis
We next investigated which step along the autophagocytic pathway requires optineurin, NDP52 and T6BP. In HeLa cells, a triple siRNA knockdown of T6BP, NDP52 and optineurin (TNO) does not significantly affect the steady-state level of autophagy as measured by conversion of LC3-I to LC3-II ( Fig. 5c,d ). However, a triple knockdown for T6BP, NDP52 and optineurin causes a significant reduction in autophagosome formation under basal conditions or following the induction of autophagy with the MG132 inhibitor, characterized by a decrease in LC3-I to LC3-II conversion in the presence of bafilomycin A1 (Fig. 5c,d and Supplementary Fig. S5b ). In addition, TNO siRNA in HeLa cells stably expressing RFP-GFP-LC3 also leads to a higher correlation of RFP/GFP signals, indicating a defect in autophagosome-lysosome fusion ( Fig. 5e ). Thus, optineurin, T6BP and NDP52 act as autophagy receptors, linking autophagy cargo to LC3 membranes, thereby promoting autophagosome biogenesis, but also have a role during autophagosome-lysosome fusion.
Tom1 interacts with myosin VI
The Drosophila homologue of the Tom1 protein family, CG3529, which is an alternative endosomal sorting complex required for transport (ESCRT) class 0, was recently identified as a myosin VI binding partner [23] [24] [25] . As the ESCRTs are required for autophagosome maturation 26 , we investigated whether Tom1 and myosin VI interact in mammalian cells and whether Tom1 is required for autophagy. Myosin VI and Tom1, as well as its close homologue Tom1L2, interact in mammalian cells as they can be co-immunoprecipitated with myosin VI antibodies ( Fig. 6a ). Using a mammalian two-hybrid assay 9,10,27 , we show that Tom1 binds to myosin VI through the WWY motif and not through the RRL motif, which binds optineurin, NDP52 or T6BP. The myosin VI binding site on Tom1 resides within the final 104 amino acids of the C terminus ( Fig. 6b ). Myosin VI and Tom1 co-localize on vesicles located along the cell periphery, which are positive for endosomal markers APPL1, GIPC and Rab5 ( Fig. 6c and Supplementary Fig. S6a,b ). In the absence of Tom1 and Tom1L2, myosin VI is lost from endosomes (Fig. 6d) , and accumulates on F-actin structures throughout the cell ( Supplementary Fig. S7 ). A partial effect was observed following knockdown of the myosin VI binding partner GIPC; however, the loss of T6BP, NDP52 or optineurin did not affect myosin VI localization ( Fig. 6d and Supplementary Fig. S6c ). Thus, the Tom1 protein family is a newly identified class of myosin VI adaptor proteins that are important for targeting myosin VI to endocytic structures in mammalian cells.
Loss of Tom1 inhibits the maturation of autophagosomes and their subsequent fusion with lysosomes
Next, we determined whether Tom1 is required for autophagy. siRNAmediated knockdown of Tom1 leads to an accumulation of LC3-II (Fig. 7a,b and Supplementary Fig. S8a ), and an increase in the number of LC3-positive autophagosomes and p62-positive punctae visualized by immunofluorescence microscopy (Fig. 7c,d and Supplementary Fig.  S8b) , very similar to the phenotype observed in myosin-VI-knockdown cells ( Fig. 1a-d ). In the HeLa RFP-GFP-LC3 stable cell line, the loss of (d) RPE cells with stable expression of GFP-myosin VI tail were subjected to mock or Tom1 siRNA transfection followed by western blot analysis (left) and immunofluorescence microscopy (middle) to evaluate GFP-myosin VI tail localization. Cells were either fixed directly or saponin-extracted before fixation. Quantification (right) was performed on RPE cells stably expressing GFP-myosin VI tail and transfected with mock, Tom1 or TNO siRNA. Cells were processed for immunocytochemistry, immunolabelled for GFP and nuclei labelled with Hoechst followed by quantification of GFP-myosin VI tail punctae per cell using an automated Cellomics VTi microscope. More than 600 cells per group from n = 3 independent experiments were analysed and are represented as the mean number of GFP-myosin VI tail punctae per cell (±s.d.). Scale bars, 20 µm. Uncropped images of blots are shown in Supplementary Fig. S9 .
Tom1 expression leads to an accumulation of LC3-positive, yellow autophagosomes that are cathepsin-D-and Lamp1-negative (Fig. 7e,f and Supplementary Fig. S2a ). We also observed in Tom1-knockdown cells a defect in protein aggregate clearance and thus an increase in the number of cells with multiple p62-and LC3-positive HttQ72-GFP aggregates ( Fig. 7g and Supplementary Fig. S3 ), phenocopying the knockdown of myosin VI (Fig. 2d,e and Supplementary Fig. S3 ). Given the very similar requirement for Tom1 and myosin VI during late stages of autophagy, we next examined whether Tom1 is recruited to autophagosomes and whether this localization is myosin VI dependent. As shown in Fig. 8a , endogenous Tom1 is present on LC3-positive autophagosomes. However, siRNA knockdown of myosin VI causes an increase in the number of Tom1-positive vesicles that are adjacent to, but not completely co-localizing with, LC3-positive autophagosomes, suggesting a defect in docking or fusion of these vesicles with autophagosomes ( Fig. 8a) . In summary, myosin VI and Tom1 function together in the final stages of autophagy, because the loss of either protein leads to an accumulation of autophagosomes unable to mature to an autolysosome.
Myosin VI mediates delivery of endocytic cargo to autophagosomes
As myosin VI and Tom1 are both present on the same endosomal compartment and their loss significantly affects autophagy flux, we next determined whether their requirement for autophagosome maturation is linked to their function in the endocytic pathway. To label the endocytic pathway, RPE cells stably expressing GFP-LC3 were pulselabelled with dextran followed by treatment with the MG132 inhibitor. Confocal immunofluorescence microscopy revealed a considerable co-localization of LC3-positive autophagosomes with fluorescently labelled dextran (Fig. 8b) . However, following myosin VI depletion by siRNA transfection, a significant reduction in the co-localization between LC3 and dextran was observed (Fig. 8b,c) . The delivery of endocytosed dextran to LC3-positive autophagosomes was confirmed at the ultrastructural level (Fig. 8d ). Representative immuno-electron micrographs of LC3-and dextran-positive amphisomes indicate that on average the LC3-and dextran-positive organelles contain darker, denser content and more endocytosed dextran in mock-treated cells when compared with knockdown cells, which suggests a possible delay in the maturation of LC3-positive structures in the absence of myosin VI or Tom1 (Fig. 8d ). We conclude that myosin VI, by docking to its autophagy adaptors, delivers Tom1-positive endosomes to autophagosomes, thus facilitating autophagosome maturation and fusion with the lysosome (Supplementary Fig. S8c ).
DISCUSSION
Here we demonstrate for that the unique reverse-directed myosin VI plays a crucial role in autophagy. Myosin VI depletion in the knockout mouse and in siRNA knockdown cells leads to an abundant accumulation of autophagosomes due to a lysosomal fusion defect and causes a reduced rate of protein aggregate clearance, but has no significant effect on autophagosome biogenesis. These phenotypes are mirrored by Tom1, an ESCRT-0 component, which we identify as a myosin VI binding partner in mammalian cells. We demonstrate that myosin VI is required for the short-range movement and/or fusion of Tom1-positive endosomes to autophagosomes and the delivery of endocytic cargo to LC3-positive organelles. Live-cell video microscopy highlights the dynamic approach, association and occasional fusion of myosin-VI-containing vesicles with autophagosomes. These vesicles may originate from a subpopulation of endosomes underneath the plasma membrane, which contain myosin VI, Tom1, Rab5 and APPL1 ( Fig. 6 and Supplementary Fig. S6a ), suggesting that myosin VI is involved in the delivery of endocytic membranes to the autophagosome. Indeed, we demonstrate that trafficking of endocytosed dextran to autophagosomes is dependent on myosin VI. Targeting of myosin VI involves the RRL motif that binds optineurin, NDP52 and T6BP, three myosin VI adaptor proteins that contain a UBD and a LIR (ref. 28) . Although optineurin and NDP52 have been specifically implicated in innate immunity 7, 8 , we demonstrate that they have a more general role in selective autophagy. We also define T6BP as a newly identified autophagy receptor. In all three proteins, the ubiquitin-binding site overlaps with the myosin VI binding region, which suggests that they may have a dual function. First, during autophagosome biogenesis, they may act similarly to p62 as adaptors between ubiquitylated cargo and LC3-conjugated membranes 28 , because depletion of optineurin, T6BP or NDP52 leads to a defect in autophagosome formation. Second, these autophagy receptors may bind to LC3 on the outer limiting membrane of the autophagosome and to myosin VI instead of ubiquitin, thereby recruiting this motor and possibly associated membranes to autophagosomes ( Supplementary  Fig. S8c ). The failure in autophagosome-lysosome fusion, associated with myosin VI depletion, may be caused by defects in autophagosome maturation due to lack of delivery, docking or fusion of endosomal membranes containing the ESCRT-0 component Tom1.
Tom1, through its WWY motif, recruits myosin VI to endosomal membranes and knockdown of Tom1 leads to an accumulation of autophagosomes attributed to a lysosomal fusion defect. Tom1 has not previously been implicated in autophagy, although dysfunction in other members of the ESCRT machinery have been linked to similar autophagy defects and to neurodegeneration 26, 29 .
Autophagosomes are surrounded by an actin filament network (Fig. 3d ) that is required for efficient autophagosome-lysosome fusion 30 . Myosin VI may be involved in short-range movement and/or tethering/anchoring of Tom1-containing endosomes to actin filaments surrounding the autophagosome. The delivery of endosomes is a process shown to be required for autophagosome maturation 1, 31 . These proposed functions of myosin VI are in line with the known motor properties of this myosin as a slow-moving motor with a maximum speed of about 60-100 nm s −1 .
Myosin VI is expected to fulfil multiple unique and even fundamental functions in cells owing to its distinct movement along actin filaments. Myosin VI functions at various steps along endocytic and secretory membrane trafficking pathways owing to its interactions with a variety of adaptor proteins. The autophagy pathway is not permanently activated, but is induced by specific stimuli, whereby existing proteins and pathways such as, for example, myosin VI and the ESCRT machinery are used to mediate high autophagic flux. Similarly to myosin VI, ESCRT proteins can function in numerous different fundamental processes such as sorting in the endocytic pathway, multivesicular body formation, virus budding, cytokinesis as well as autophagy 32 .
These diverse cellular roles of myosin VI are reflected in the profound phenotypic abnormalities in multiple systems that are slowly emerging from the myosin-VI-knockout mouse and some phenotypes are suggestive of autophagy defects, including astrogliosis in the brain and decreased body weight. During autophagy, myosin VI may play a crucial, proactive role regulating the fusion of Tom1-positive endosomal membranes with autophagosomes and in addition, similar to its role in regulating secretory vesicle fusion events at the plasma membrane 33, 34 , may also be involved in the fusion of the autophagosome with the lysosome and the release of its content for degradation.
METHODS
Methods and any associated references are available in the online version of the paper. 
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METHODS Antibodies and reagents. The antibodies used were as follows: LC3 (M152-3; 1:200 immunofluorescence microscopy (IF)) monoclonal antibody (MBL International); Rab5 (610724; 1:100 IF), EEA1 (610457; 1:100 IF), EGFR (610016; 1:1,000 western blotting (WB)) and p62 (610832; 1:250 IF) monoclonal antibodies (BD Biosciences); actin (A2066; 1:10,000 WB), LC3 (L7543; 1:2,000 WB), GIPC (sc-9648; 1:100 IF), APPL1 (sc-67402; 1:100 IF) and Atg5 (A2859;1:1,000 WB) antibodies (Sigma-Aldrich); Tom1L2 (ab96320; 1:100 IF, 1:1,000 WB) and GFP (ab6556; 1:50 electron microscopy (EM)) polyclonal antibodies and GFP (ab1218;1:1,000 IF) monoclonal antibody (Abcam); GFP (A11122;1:2,000 WB, 1:1,000 IF) polyclonal antibody (Invitrogen); and DsRed (632496; 1:500 IF) polyclonal antibody (Clontech). Lamp1 (H4A3; 1:250 IF) monoclonal antibody was purchased from the Developmental Studies Hybridoma Bank (University of Iowa). Affinity-purified rabbit polyclonal antibodies against myosin VI, T6BP, NDP52 and optineurin were generated as previously described 9, 10, 35 . Bafilomycin A1 (B1793) and EGF were purchased from Sigma-Aldrich. Torin1 was a gift from D. M. Sabatini (Whitehead Institute, Boston, USA). The MG132 inhibitor was purchased from Millipore and protein A conjugated to 5 and 15 nm colloidal gold from the Department of Cell Biology, University of Utrecht. Rabbit anti-Texas-red (A-639;1:50 EM) was purchased from Life Technologies and Texas-red-labelled lysine-fixable dextran (relative molecular mass 10,000) from Invitrogen.
Cell culture and transfections. HeLa cells were cultured in RPMI and Chinese hamster ovary (CHO) cells in Ham's F-12, supplemented with 10% FBS, 2 mM glutamine, 100 U ml −1 penicillin and 100 µg ml −1 streptomycin. RPE cells were cultured in DMEM/Ham's F-12 (50:50), 10% FBS, 2 mM glutamine, penicillin/streptomycin and 30 mM sodium bicarbonate. All complementary DNA transfections were performed using Fugene6 according to the manufacturer's instructions (Roche Diagnostics). Stable cell lines were generated using pIRES neo2 plasmids and subsequent selection in G418 (Invitrogen). For dextran uptake, cells were pulse labelled with Texas-red-dextran for 4 h followed by chase into complete media with or without 1 µM MG132 for 2 h before fixation. For EGFR degradation assays, cells were treated with 20 ng ml −1 EGF for the indicated times before western blot analysis.
All ON-TARGETplus SMARTpool or single target siRNA oligonucleotides were purchased from Dharmacon (Abgene House) and subsequently transfected into cells using Oligofectamine according to the manufacturer's instructions (Invitrogen). For efficient knockdown, cells were transfected twice with siRNA on day 1 and 3 and on day 5 the cells were processed for the corresponding assay and the efficiency of protein depletion was assessed by western blotting. siRNA sequences are listed in Supplementary Table S1 .
Primary cultures of embryonic fibroblasts and cortical neurons.
All experiments were conducted in accordance with the United Kingdom Animals (Scientific Procedure) Act of 1986. Embryonic fibroblasts and cortical neurons were established from wild-type and SV embryos at embryonic day E15-E17 of development from euthanized pregnant females. For preparation of fibroblasts, skin, limbs and muscle tissue was dissected from the embryos, and the tissue was minced and incubated in trypsin containing 300 U ml −1 DNAse (Invitrogen) for 20 min at 37 • C. Following the addition of growth medium (DMEM with 10% FBS, glutamine, penicillin and streptomycin), the digested tissue was triturated through a glass Pasteur pipette, centrifuged, resuspended in growth media and plated onto tissue-culture treated dishes. Cells were allowed to adhere and recover for 24 h and cells were used at early passage. For preparation of cortical neurons, embryonic brains were dissected, meninges removed, and cortices were separated from the rest of the brain. Cortices were minced, triturated through a Pasteur pipette, centrifuged, and resuspended in Neurobasal A media (Invitrogen) with B27 supplement (Invitrogen), penicillin and streptomycin. Cells were plated onto poly-l-ornithine (Sigma)-coated tissue culture dishes and experiments were performed 5-7 days post-plating. Each experiment was performed from separate litters.
Plasmids. GFP-myosin VI and GFP-myosin VI tail wild type, RRL to AAA and WWY to WLY constructs were generated as previously described 34, 36 . The myosin VI ubiquitin-binding mutant A1013G was generated by the QuikChange site-directed mutagenesis. The full-length GFP-myosin VI wild-type oligonucleotide 07 siRNAresistant construct was generated by the insertion of three silent mutations by site-directed mutagenesis. Stable cell lines were obtained by subcloning constructs into pIRESneo2 followed by transfection and selection with G418 before pooling positive cells and enrichment by fluorescence-activated cell sorting. GFP-tagged optineurin, T6BP and NDP52 constructs were generated as previously described 9, 10 . The D474N mutant of optineurin was generated by site-directed mutagenesis. Cherry-LC3 was a gift from G. Hesketh (University of Cambridge, UK). The GFP-LC3 construct created by K. Kirkegaard 37 (Addgene plasmid 11546) and the RFP-GFP-LC3 construct created by T. Yoshimori 18 (ptfLC3; Addgene plasmid 21074) were obtained from Addgene and subcloned into pIRESneo2 for the generation of stable cell lines. The HttQ72 construct created by S. Lindquist 38 (Addgene plasmid 1179) was obtained from Addgene and subsequently subcloned into pEGFPc3. To generate lentivirus, HttQ72-GFP was cloned into the pLNCX2 vector and lentivirus was produced using the Lent-X Lentiviral expression system from Clontech. Stable expressing cell lines were generated by lentiviral transduction in the presence of 5 µg ml −1 Polybrene.
Mammalian two-hybrid assay. The binding site for Tom1 and Tom1L2 on myosin VI was mapped by subcloning wild-type and mutants ( WWY, RRL) of the myosin VI tail region (amino acids 840-1,294) into the bait vector, pM (BD Clontech), and full-length Tom1 and Tom1L2 were subcloned into the prey vector, pVP16 (BD Clontech). To map the binding site of myosin VI on Tom1, the myosin VI globular tail region (amino acids 1,036-1,294) was used as bait and various truncated Tom1 constructs (amino acids 1-180, 181-320, 299-492, 1-388) amplified by PCR and verified by sequencing were used as prey. The mammalian two-hybrid assay was performed in CHO cells as previously described 39 .
Western blot and co-immunoprecipitation. Whole-cell lysates were collected in 2× SDS-sample buffer and boiled 5 min before being processed for western blot analysis as previously described 33 . Quantitative western blotting was performed following protein transfer to Immobilon-FL PVDF (Millipore) and immunoblotting with goat-647-conjugated secondary antibodies before scanning on a LI-COR Odyssey Infrared Imaging system (LI-COR Biosciences). The integrated intensities of the LC3-II protein bands, following background correction, were normalized to an actin control before quantification.
Co-immunoprecipitation experiments were performed from LNCAP prostate cancer cell lysates, collected in ice-cold lysis buffer (50 mM Tris at pH 7.4, 150 mM NaCl, 1% NP-40, 1 mM EGTA, 5 mM ATP, 5 mM MgCl2 and complete protease inhibitor (Roche)) and processed as previously described 35 . Samples were run on SDS-PAGE and immunoblotted using Clean-Blot IP detection reagent (Thermo Fisher Scientific).
Immunofluorescence microscopy. Cells were plated on glass coverslips, fixed in 4% formaldehyde and permeabilized in 0.02% Triton X-100 in PBS. Alternatively, to reduce the cytoplasmic background, cells were extracted in 0.02% saponin in PBS for 30 s before fixation. For cathepsin D and Lamp1 immunostaining, fixation was performed in cold methanol for 10 min. Fixed cells were blocked in 1% BSA in PBS, before incubation with primary antibodies. AlexaFluor488-, 568-or 647-conjugated secondary antibodies (Invitrogen) and 568-conjugated phalloidin (Invitrogen) were used for detection. Images were captured on either a Zeiss Axiovert epifluorescence microscope equipped with Hamamatsu ORCA-R2 CCD (charge-coupled device) camera driven by SIMPLE PCI Software or on a Zeiss LSM710 confocal microscope with Zeiss ZEN software. Live-cell video microscopy was acquired either on a Zeiss LSM710 confocal microscope or on a Zeiss AxioObserver Z1 inverted microscope with a Plan-Apochromot ×63/1.40 oil DIC objective and an AxioCam MR3 equipped with a spinning-disc module using Zeiss Axiovision software. For live-cell studies, images were captured every 10 s for a period of 10 min. Images were processed with Adobe Photoshop CS4 and assembled in Adobe Illustrator CS4.
For co-localization analysis, Pearson's coefficients or Mander's overlap coefficients were calculated using either ImageJ software with Just Another Colocalization Plugin (JACoP; National Institutes of Health), Volocity software v.6.0.1 (PerkinElmer) or Imaris software v.7.4 (Bitplane AG). For quantification of co-localization from cells expressing the RFP-GFP-LC3 fusion protein, ImageJ software with JACoP was used to calculate a Pearson's coefficient based on the correlation in GFP and RFP signal overlap in greater than 100 cells from at least two independent experiments. All other co-localization calculations were performed on >10 cells from at least two independent experiments.
Automated quantification of p62 aggregates, GFP-LC3 autophagosome size, p62 punctae, LC3 punctae and the number of GFP-myosin VI tail punctae was performed on cells plated on a black PerkinElmer 96-well view plate using an ArrayScan VTi HCS Microscope (Cellomics) using the Spot Detector V4 algorithm application. Immunocytochemistry was performed, nuclei were labelled with Hoechst to identify each individual cell, and the average fluorescence intensity, GFP-LC3 vesicle area or number of GFP-myosin VI tail punctae was calculated per cell from 6 wells, with >250 cells per well for each condition. The GFP-LC3 vesicle area is represented in square micrometres. The results are from three independent experiments.
Immunogold electron microscopy. RPE cells expressing GFP-LC3, pulselabelled with Texas-red-dextran for 16 h followed by a chase of 4 h, were subsequently processed for immunogold labelling as previously described 40 . Sequential immunolabelling of Texas red and GFP was performed at room temperature using the protein-A-gold technique 41 . The sections were washed, contrasted by embedding in 1.8% methyl cellulose/0.3% uranyl acetate, and airdried before observation in a Philips CM100 transmission electron microscope at an operating voltage of 80 kV.
Presentation of data and statistics. All graphs were produced using GraphPad Prism software and the error bars represent the standard deviation. Box and whisker plots represent the median, 25th and 75th percentile, and the minimum and maximum values. Statistics were calculated using either unpaired Student t -tests or one-way analysis of variance followed by a Bonferroni multiple-comparison post-hoc test. Figure S5 The autophagy adaptors, T6BP, NDP52, and optineurin, localise to autophagosomes and are required for autophagosome biogenesis. (a) Optineurin localisation to autophagosomes requires its ubiquitin-binding motif, while the ubiquitin-and myosin VI-binding region is dispensable for T6BP and NDP52 localisation to autophagosomes. RPE cells with stable expression of cherry-LC3 were transiently transfected with GFP-optineurin wild-type and D474N mutant, with GFP-T6BP wild-type, C688A and C715A zinc finger mutants, or with GFP-NDP52 wild-type and zinc finger truncation mutant (aa 1-425), followed by treatment with 250 nM Torin1 for 3 hours to induce autophagy. Immunofluorescence microscopy was performed and colocalisation of optineurin, T6BP, and NDP52 with LC3 was evaluated. Inserts provide higher magnification of boxed regions. Scale bar, 20 µm. (b) Western blot analysis of T6BP, NDP52, and optineurin (TNO) triple siRNA knockdown in Hela cells following treatment with 1 µM MG132 for the indicated times or in the presence of 100 nM Bafilomycin A1 for 2 hours.
Immunoblotting was performed to the indicated proteins. Figure S8 Loss of Tom1 leads to an accumulation of p62-and LC3positive autophagosomes and together with myosin VI is required for autophagosome maturation. (a) Western blot analysis of lysates harvested from Hela cells depleted of Tom1 with siRNA and treated with 1 µM MG132 for indicated times or in presence of 100 nM Bafilomycin A1 for 2 hours. Immunoblotting was performed to the indicated proteins. (b) Confocal immunofluorescence microscopy of mock and Tom1 siRNA treated Hela cells immunostained for p62 (green). Nuclei were stained with Hoechst (blue). Scale bar, 20 µm. (c) Cartoon model illustrating the potential mechanistic function of myosin VI during autophagy. Herein we present three possible scenarios for the molecular function of myosin VI at autophagosomes. 1. Functioning as a monomeric actin tether to deliver Tom1-expressing endosomes required for autophagosome maturation. 2. Acting as a dimeric motor bridging endosomal and autophagic compartments through interactions with Tom1 and the autophagy adaptors (optineurin, NDP52, tax1bp1). 3. Following Tom1dependent targeting to autophagosomes myosin VI interacts with the autophagy adaptors and tethers autophagosomes to the actin cytoskeleton required for fusion with the lysosomal compartment. E = endosome, L = lysosome. 
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